Flaps Morph for HIV Protease: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
Eric Martz (talk | contribs)
No edit summary
Eric Martz (talk | contribs)
No edit summary
 
(43 intermediate revisions by the same user not shown)
Line 1: Line 1:
<StructureSection load='' size='350' side='right' caption='HIV protease: morph of flaps opening/closing ([[1hxw]] &harr; [[1tw7]]' scene=''>
<StructureSection load='' size='350' side='right' caption='HIV protease: morph of flaps opening/closing ([[1hxw]] &harr; [[1tw7]]).' scene='83/836583/Morph/8'>
The genome of HIV codes for synthesis of a polyprotein (UniProt [https://www.uniprot.org/uniprot/P04585 P04585 (POL_HV1H2)]) that requires cutting by HIV protease in order to be separated into individual mature proteins required for virus maturation<ref name="wide-open">PMID:16338417</ref>. Drugs that inhibit HIV protease prevent the virus from replicating, and are [[Molecular Playground/HIV Protease Inhibitor|crucial components of anti-HIV therapies]].
The genome of HIV codes for synthesis of a polyprotein (UniProt [https://www.uniprot.org/uniprot/P04585 P04585 (POL_HV1H2)]) that requires cutting by HIV protease in order to be separated into individual mature proteins required for virus maturation<ref name="wide-open">PMID:16338417</ref>. Drugs that inhibit HIV protease prevent the virus from replicating, and are [[Molecular Playground/HIV Protease Inhibitor|crucial components of anti-HIV therapies]].


The proteolytic active site of HIV protease is [[Immunodeficiency virus protease|covered by two "flaps"]]. It is believed that these flaps must open to enable substrate polyprotein to enter the active site. Drugs that inhibit HIV protease tend to "lock" the flaps closed<ref>PMID:22291339</ref>. Mutations in HIV protease that confer resistance to inhibitor drugs often involve changes to the flaps<ref name="wide-open" />. The ''active site expansion'' hypothesis states that mutations responsible for multi-drug resistance expand the active site cavity, thereby reducing drug affinity<ref name="wide-open" />.
The proteolytic active site of HIV protease is [[Immunodeficiency virus protease|covered by two "flaps"]]. It is believed that these flaps must open to enable substrate polyprotein to enter the active site. Drugs that inhibit HIV protease tend to "lock" the flaps closed<ref>PMID:22291339</ref>. Mutations in HIV protease that confer resistance to inhibitor drugs often involve changes to the flaps<ref name="wide-open" />. The ''active site expansion'' hypothesis states that mutations responsible for multi-drug resistance expand the active site cavity, thereby reducing drug affinity<ref name="wide-open" />.


There are [[Immunodeficiency virus protease 3D structures|hundreds of HIV protease crystal structures]]. When crystallized with bound inhibitor, the flaps have nearly always been closed<ref name="processes">Yu, Y. ''et al.'', Structural insights into HIV-1 protease flap opening processes and key intermediates. 2017 RSC Advances, '''7''':45121-8. '''NOT IN PUBMED.''' [https://pubs.rsc.org/en/content/articlehtml/2017/ra/c7ra09691g OPEN ACCESS]. DOI: [https://doi.org/10.1039/C7RA09691G 10.1039/C7RA09691G].</ref>. Inhibitor-free  crystal structures have been classified into '''closed, semi-open,''' and '''wide open'''<ref name="processes" />. As of 2017, no crystal structure has captured a '''fully open''' conformation, defined as a distance of >13 Å between isoleucine 50's at the tips of the flaps<ref name="wide-open" />.
There are [[Immunodeficiency virus protease 3D structures|hundreds of HIV protease crystal structures]]. When crystallized with bound inhibitor, the flaps have nearly always been closed<ref name="processes">Yu, Y. ''et al.'', Structural insights into HIV-1 protease flap opening processes and key intermediates. 2017 RSC Advances, '''7''':45121-8. '''NOT IN PUBMED.''' [https://pubs.rsc.org/en/content/articlehtml/2017/ra/c7ra09691g OPEN ACCESS]. DOI: [https://doi.org/10.1039/C7RA09691G 10.1039/C7RA09691G].</ref>. Inhibitor-free  crystal structures have been classified into '''closed, semi-open,''' and '''wide open'''<ref name="processes" />. As of 2017, no ligand-free crystal structure has captured a '''fully open''' conformation, defined as a distance of >13 Å between isoleucine 50's at the tips of the flaps<ref name="wide-open" /> (but see [[4npt]] in the table below).


In the case of mutant [[1tw7]], about 100 water molecules reside in the active site, forming a hydrogen-bonded scaffold holding the flaps open<ref name="wide-open" />.  
<center>{{Template:Green_links_zoom}}</center>
Here is shown a morph between a closed HIV protease ([[1hxw]]) and a "wide open" protease ([[1tw7]], <scene name='83/836583/Morph/8'>restore initial scene</scene>). The catalytic <font color="red">'''Asp 25's are red'''</font>. (Note that "wide open" is not "fully open" -- see above.)
<center>{{Template:Button_Toggle_Animation2}}</center>
''Click the Toggle Animation Button above to '''start''' these animations if needed.''
* <scene name='83/836583/Morph/11'>Morph of ribbon/cartoon with</scene> <font color="magenta">'''flap glycines in magenta'''</font> (Gly 40, 48, 49, 51, 52).
* <scene name='83/836583/Morph/12'>Morph of ribbon/cartoon with flaps highlighted</scene> in <font color="orange">'''orange'''</font>. (Flaps: residues 42-58.)
* <scene name='83/836583/Morph/13'>Morph of spacefilling rendition</scene> with flaps highlighted in <font color="orange">'''orange'''</font>.
 
In the case of mutant [[1tw7]], about 100 water molecules (not shown) reside in the active site, forming a hydrogen-bonded scaffold holding the flaps open<ref name="wide-open" />.  


</StructureSection>
</StructureSection>
==Relevant Resources==
===YouTube===
*[https://www.youtube.com/watch?v=dDo_s6a3wcM HIV protease action]: Excellent half-minute video from the [[PDB]] simulating polyprotein entering protease active site between the flaps, polyprotein hydrolysis, and binding of saquinavir locking the protease closed, inactivating it.
*[https://www.youtube.com/watch?v=9XfJ1NGlUxc Mechanism and Inhibition of Aspartyl Protease Enzymes] (which include HIV protease) explained by [https://www.chemistry.gatech.edu/people/evans/michael Michael Evans (Georgia Tech)]. Excellent detailed explanation of the catalytic mechanism and design of inhibitors.
*[https://www.youtube.com/watch?v=lcLbmuPH4VM Wide-opening of the HIV-1 protease active site]. 50 ns all-atom molecular dynamics simulation of
*[https://www.youtube.com/watch?v=fDFNGo9UfBI Coarse-grained Brownian dynamics simulation]. 2 ns simulation shows flaps opening and substrate binding.
===Other External Resources===
*[https://pdb101.rcsb.org/motm/6 HIV-1 Protease] in the [[PDB|RCSB PDB]] Molecule of the Month.
*[https://en.wikipedia.org/wiki/HIV-1_protease HIV-1 Protease] in Wikipedia. Includes a link to this page.
*[https://en.wikipedia.org/wiki/Discovery_and_development_of_HIV-protease_inhibitors Discovery and development of HIV-protease inhibitors] in Wikipedia.
===Well-Developed, in Proteopedia===
*[[Immunodeficiency virus protease]] includes morphs of flap movements and saquinavir binding. ([[HIV-1 protease]] redirects here.)
*[[Immunodeficiency virus protease 3D structures]] lists hundreds of crystal structures of HIV proteases.
*[[HIV Protease Inhibitor Resistance Profile]]
*[[Molecular Playground/HIV Protease Inhibitor]] includes an animated simulation of the protease inhibitor Ritonavir binding to the protease.
*[[Group:SMART:HIV-1 Subtype C Protease]]
*[[Protease]]
*[[Human Immunodeficiency Virus]]
*[[Journal:Acta_Cryst_D:S2059798319011355]] Comparison of a retroviral protease crystallized as a monomer and a dimer.
===Sandboxes in Proteopedia===
*[[User:Tsung-Yi_Lin/Sandbox]]
*[[User:Dan_Huettner/Sandbox_1]], [[User:Dan_Huettner/Sandbox_3]]
*[[User:David Canner/Sandbox HIV]]
*[[Sandbox 645]]
*[[Sandbox_Reserved_712]]
*[[Sandbox Reserved 955]]
*[[User:Nicole Maille/Sandbox 1]]
===Flaps in Other Proteins===
These were found by searching for "flaps" in Proteopedia.
*[[Sandbox 215]]: Omega flaps in cholesterol ester transfer protein.
*[[Fatty acid amide hydrolase]], [[Sandbox_Reserved_921]], [[Sandbox_Reserved_922]]
==Methods==
[[1hxw]], containing the inhibitor Ritonavir, was selected in part because it is more closed than an early, unliganded wild type structure: Ile50 to Gly27 is 11.6 Å in 1hxw, vs. 16.9 Å in [[3phv]].  (The only mutation in 1hxw is S37N.) [[1tw7]], with "wide open" flaps, was selected in part because its asymmetric unit contains two chains. It has many drug-resistance mutations (see table below).
The [[morph]] was generated by [[Morphs#Proteopedia_PyMOL_Morpher|Proteopedia's PyMOL Morpher]]. 1tw7 was pre-aligned with 1hxw, aligning only residues 1-35. Alignment was done in the [[Jmol/Application|Jmol Java Application]] with the following script:
<pre>load =1hxw # "=" means load from RCSB PDB.
load append =1tw7 # add this model rather than replacing the previously loaded model.
frame all # display both models.
background white
trace only
color polymer
delay 2.0
compare {2.1} {1.1} subset {*.ca} atoms {1-35} {1-35} rotate translate 2.0 # moves model 2 to align with model 1
select 2.1 # "2.1" is the second model loaded
write 1tw7-aligned-to-1hxw.pdb</pre>


<table class="wikitable" style="text-align:center;">
<table class="wikitable" style="text-align:center;">
Line 21: Line 80:
Year
Year
   </td><td>
   </td><td>
Resolution; Rfree*
[[Resolution]]; [[Rfree|R<sub>free</sub>]]*
   </td><td>
   </td><td>
Asymm. Unit
[[Asymmetric unit|Asymm. Unit]]
   </td><td>
   </td><td>
Ile50 dist.
Ile50 dist.&dagger;
   </td><td>
   </td><td>
Mutations; Comments
Mutations; Comments
Line 43: Line 102:
12.25 Å
12.25 Å
   </td><td>
   </td><td>
I10L, N25D, V36M, L46M, V54I, V62I, P63L, V71A, A82V, V84I, M90L
L10I, D25N, M36V, M46L, I54V, I62V, L63P, A71V, V82A, I84V, L90M
   </td><td>
   </td><td>
[[3phv]]
[[3phv]]
Line 59: Line 118:
12.2 Å
12.2 Å
   </td><td>
   </td><td>
K7Q
Q7K
   </td><td>
   </td><td>
   </td>
   </td>
Line 74: Line 133:
12.19 Å
12.19 Å
   </td><td>
   </td><td>
K7Q, I33L, R41K, I63L
Q7K, L33I, K41R, L63I
   </td><td>
   </td><td>
   </td>
   </td>
Line 108: Line 167:
11.9 Å
11.9 Å
   </td><td>
   </td><td>
V10I, N25D, E35D, V36I, L46M, A82T; Structure unreliable according to Rfree.
V10I, D25N, D35E, I36V, M46L, T82A; Structure unreliable according to Rfree.
   </td><td>   
   </td><td>   
</td></tr></table>
</td></tr></table>
*Rfree is categorized by [[FirstGlance in Jmol]] as A (Average), BTA (Better Than Average), U (Unreliable), WTA (Worse Than Average) at the corresponding resolution.
<nowiki>*</nowiki>[[Rfree|R<sub>free</sub>]] is categorized by [[FirstGlance in Jmol]] as A (Average), BTA (Better Than Average), U (Unreliable), WTA (Worse Than Average) at the corresponding resolution.
 
<br>
 
&dagger; Distance between the Ile50 alpha carbons in each chain. These are near the tips of the flaps, and this distance is commonly used in the literature to measure the openness of the flaps.
* I did not finish examining hits via google for 'hiv protease flaps animation'
 
 
*[[Immunodeficiency virus protease]] includes morphs of flap movements and saquinavir binding. ([[HIV-1 protease]] redirects here.)
*[[Immunodeficiency virus protease 3D structures]] lists hundreds of crystal structures of HIV proteases.
*[[HIV Protease Inhibitor Resistance Profile]]
*[[Molecular Playground/HIV Protease Inhibitor]] includes an animated simulation of the protease inhibitor Ritonavir binding to the protease.
*[[Group:SMART:HIV-1 Subtype C Protease]]
*[[Protease]]
*[[Human Immunodeficiency Virus]]
*[[Journal:Acta_Cryst_D:S2059798319011355]] Comparison of a retroviral protease crystallized as a monomer and a dimer.
 
 
*[[User:Tsung-Yi_Lin/Sandbox]]
*[[User:Dan_Huettner/Sandbox_1]], [[User:Dan_Huettner/Sandbox_3]]
*[[User:David Canner/Sandbox HIV]]
*[[Sandbox 645]]
*[[Sandbox_Reserved_712]]
*[[Sandbox Reserved 955]]
*[[User:Nicole Maille/Sandbox 1]]
 
 
*[[Sandbox 215]]
*[[Fatty acid amide hydrolase]], [[Sandbox_Reserved_921]], [[Sandbox_Reserved_922]]




==References==
<references />
<references />

Latest revision as of 02:00, 24 February 2020

The genome of HIV codes for synthesis of a polyprotein (UniProt P04585 (POL_HV1H2)) that requires cutting by HIV protease in order to be separated into individual mature proteins required for virus maturation[1]. Drugs that inhibit HIV protease prevent the virus from replicating, and are crucial components of anti-HIV therapies.

The proteolytic active site of HIV protease is covered by two "flaps". It is believed that these flaps must open to enable substrate polyprotein to enter the active site. Drugs that inhibit HIV protease tend to "lock" the flaps closed[2]. Mutations in HIV protease that confer resistance to inhibitor drugs often involve changes to the flaps[1]. The active site expansion hypothesis states that mutations responsible for multi-drug resistance expand the active site cavity, thereby reducing drug affinity[1].

There are hundreds of HIV protease crystal structures. When crystallized with bound inhibitor, the flaps have nearly always been closed[3]. Inhibitor-free crystal structures have been classified into closed, semi-open, and wide open[3]. As of 2017, no ligand-free crystal structure has captured a fully open conformation, defined as a distance of >13 Å between isoleucine 50's at the tips of the flaps[1] (but see 4npt in the table below).

Click the green links below to change the molecular scene. Drag to rotate.
Zoom the molecule with your mouse wheel, or Shift-Drag up/down.

Here is shown a morph between a closed HIV protease (1hxw) and a "wide open" protease (1tw7, ). The catalytic Asp 25's are red. (Note that "wide open" is not "fully open" -- see above.)

Click the Toggle Animation Button above to start these animations if needed.

  • flap glycines in magenta (Gly 40, 48, 49, 51, 52).
  • in orange. (Flaps: residues 42-58.)
  • with flaps highlighted in orange.

In the case of mutant 1tw7, about 100 water molecules (not shown) reside in the active site, forming a hydrogen-bonded scaffold holding the flaps open[1].


HIV protease: morph of flaps opening/closing (1hxw1tw7).

Drag the structure with the mouse to rotate

Relevant ResourcesRelevant Resources

YouTubeYouTube

Other External ResourcesOther External Resources

Well-Developed, in ProteopediaWell-Developed, in Proteopedia

Sandboxes in ProteopediaSandboxes in Proteopedia

Flaps in Other ProteinsFlaps in Other Proteins

These were found by searching for "flaps" in Proteopedia.

MethodsMethods

1hxw, containing the inhibitor Ritonavir, was selected in part because it is more closed than an early, unliganded wild type structure: Ile50 to Gly27 is 11.6 Å in 1hxw, vs. 16.9 Å in 3phv. (The only mutation in 1hxw is S37N.) 1tw7, with "wide open" flaps, was selected in part because its asymmetric unit contains two chains. It has many drug-resistance mutations (see table below).

The morph was generated by Proteopedia's PyMOL Morpher. 1tw7 was pre-aligned with 1hxw, aligning only residues 1-35. Alignment was done in the Jmol Java Application with the following script:

load =1hxw # "=" means load from RCSB PDB.
load append =1tw7 # add this model rather than replacing the previously loaded model.
frame all # display both models.
background white
trace only
color polymer
delay 2.0
compare {2.1} {1.1} subset {*.ca} atoms {1-35} {1-35} rotate translate 2.0 # moves model 2 to align with model 1
select 2.1 # "2.1" is the second model loaded
write 1tw7-aligned-to-1hxw.pdb

Wide-Open Drug-Free HIV Protease Crystal Structures[3]

PDB ID

Year

Resolution; Rfree*

Asymm. Unit

Ile50 dist.†

Mutations; Comments

Wild Type

1tw7[1]

2005

1.3 Å; WTA*

2 chains

12.25 Å

L10I, D25N, M36V, M46L, I54V, I62V, L63P, A71V, V82A, I84V, L90M

3phv

2pc0

2007

1.4 Å; BTA*

1 chain

12.2 Å

Q7K

2r8n

2008

1.2 Å; A*

1 chain

12.19 Å

Q7K, L33I, K41R, L63I

Other HIV Protease Crystal Structures With Separated Flaps

4npt

2014

1.66 Å; A*

1 chain

13.2 Å

D25N; Inhibitor is between flaps

3pj6

2011

2.25 Å; U*

1 chain

11.9 Å

V10I, D25N, D35E, I36V, M46L, T82A; Structure unreliable according to Rfree.

*Rfree is categorized by FirstGlance in Jmol as A (Average), BTA (Better Than Average), U (Unreliable), WTA (Worse Than Average) at the corresponding resolution.
† Distance between the Ile50 alpha carbons in each chain. These are near the tips of the flaps, and this distance is commonly used in the literature to measure the openness of the flaps.


ReferencesReferences

  1. 1.0 1.1 1.2 1.3 1.4 1.5 Martin P, Vickrey JF, Proteasa G, Jimenez YL, Wawrzak Z, Winters MA, Merigan TC, Kovari LC. "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. Structure. 2005 Dec;13(12):1887-95. PMID:16338417 doi:10.1016/j.str.2005.11.005
  2. Heal JW, Jimenez-Roldan JE, Wells SA, Freedman RB, Romer RA. Inhibition of HIV-1 protease: the rigidity perspective. Bioinformatics. 2012 Feb 1;28(3):350-7. doi: 10.1093/bioinformatics/btr683. PMID:22291339 doi:http://dx.doi.org/10.1093/bioinformatics/btr683
  3. 3.0 3.1 3.2 Yu, Y. et al., Structural insights into HIV-1 protease flap opening processes and key intermediates. 2017 RSC Advances, 7:45121-8. NOT IN PUBMED. OPEN ACCESS. DOI: 10.1039/C7RA09691G.

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Eric Martz